Published in J Virol on November 07, 2012
Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther (2015) 1.29
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother (2013) 0.99
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology (2013) 0.88
Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage. AIDS Res Ther (2015) 0.80
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor. J Virol (2015) 0.78
Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc. Antimicrob Agents Chemother (2013) 0.77
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology (2015) 0.76
Discordant HIV Couple. Indian J Dermatol (2014) 0.75
Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants. Retrovirology (2015) 0.75
Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. Antimicrob Agents Chemother (2015) 0.75
Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution. Front Microbiol (2017) 0.75
HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs. AIDS Res Hum Retroviruses (2016) 0.75
Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J (2016) 0.75
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell (1987) 4.84
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 3.84
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A (2000) 3.10
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol (2006) 2.97
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS (2006) 2.71
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med (1992) 2.13
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proc Natl Acad Sci U S A (1990) 1.99
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis (2010) 1.89
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol (2007) 1.77
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol (2004) 1.69
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology (2008) 1.56
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog (2007) 1.55
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol (2000) 1.54
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis (2011) 1.53
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol (2004) 1.50
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother (2007) 1.47
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol (2010) 1.47
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother (2003) 1.46
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol (2003) 1.46
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother (2006) 1.26
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr (2005) 1.24
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog (2007) 1.23
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol (2010) 1.23
In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol (2002) 1.21
Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol (1999) 1.20
Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev (2010) 1.16
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr (2010) 1.14
Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J Virol (2001) 1.12
HIV transmission and primary drug resistance. AIDS Rev (2006) 1.12
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.08
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect (2010) 1.06
A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques (2009) 1.03
Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol (2009) 1.01
Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol (2010) 1.01
HIV-1 Entry, Inhibitors, and Resistance. Viruses (2010) 1.00
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials (2010) 0.98
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
Sch-351125 and Sch-350634. Schering-Plough. Curr Opin Investig Drugs (2002) 0.94
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology (2011) 0.89
The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses (1998) 0.88
Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C. Antimicrob Agents Chemother (2011) 0.87
A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology (2011) 0.86
In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients. New Microbiol (2005) 0.82
Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5. J Chem Inf Model (2011) 0.81
Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations. Curr Opin HIV AIDS (2007) 0.79
DNA suspension arrays: silencing discrete artifacts for high-sensitivity applications. PLoS One (2010) 0.77
Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol (2007) 3.05
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol (2005) 2.17
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS (2005) 1.99
Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis (2010) 1.89
Structure of the actin crosslinking core of fimbrin. Structure (2004) 1.82
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol (2004) 1.69
HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev (2007) 1.66
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2004) 1.58
A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. Cell Host Microbe (2013) 1.56
Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat (2002) 1.54
Neighboring group participation in the transition state of human purine nucleoside phosphorylase. Biochemistry (2007) 1.53
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Identifying the important HIV-1 recombination breakpoints. PLoS Comput Biol (2008) 1.42
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol (2005) 1.42
Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care (2009) 1.37
Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev (2002) 1.36
Picomolar transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-A. Biochemistry (2004) 1.35
Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol (2007) 1.35
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J Biol Chem (2004) 1.34
Four generations of transition-state analogues for human purine nucleoside phosphorylase. Proc Natl Acad Sci U S A (2010) 1.28
In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms. J Virol (2002) 1.27
Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol (2002) 1.27
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog (2007) 1.23
Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One (2012) 1.21
Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic) (2009) 1.18
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses (2008) 1.16
Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J Virol Methods (2003) 1.14
Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol (2007) 1.14
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.08
PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol (2004) 1.08
Structure and inhibition of a quorum sensing target from Streptococcus pneumoniae. Biochemistry (2006) 1.06
A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques (2009) 1.03
Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination. Retrovirology (2006) 1.03
Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry (2002) 1.02
Sequence determinants of breakpoint location during HIV-1 intersubtype recombination. Nucleic Acids Res (2006) 1.02
Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol (2010) 1.01
Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol (2009) 1.01
HIV-1 Entry, Inhibitors, and Resistance. Viruses (2010) 1.00
The ybeY protein from Escherichia coli is a metalloprotein. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 1.00
Structure of RPE65 isomerase in a lipidic matrix reveals roles for phospholipids and iron in catalysis. Proc Natl Acad Sci U S A (2012) 0.99
Enrichment of intersubtype HIV-1 recombinants in a dual infection system using HIV-1 strain-specific siRNAs. Retrovirology (2011) 0.97
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Calculating HIV-1 infectious titre using a virtual TCID(50) method. Methods Mol Biol (2009) 0.94
Over-the-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase. Biochemistry (2003) 0.93
Sorting out the complexities of HIV-1 fitness. AIDS (2003) 0.90
Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda. Afr Health Sci (2004) 0.90
Characterizing monoclonal antibody structure by carboxyl group footprinting. MAbs (2015) 0.90
How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination. J Immunol (2002) 0.89
Methods to determine HIV-1 ex vivo fitness. Methods Mol Biol (2005) 0.88
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother (2009) 0.88
HIV-1 replicative fitness in elite controllers. Curr Opin HIV AIDS (2011) 0.88
Past, present, and future of entry inhibitors as HIV microbicides. Curr HIV Res (2012) 0.86
Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470. Mol Biochem Parasitol (2009) 0.85
Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus. J Virol (2012) 0.84
Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry. Biochemistry (2010) 0.84
Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication. J Virol (2008) 0.84
A high-throughput approach to protein structure analysis. Genet Eng (N Y) (2007) 0.83
Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism. J Clin Microbiol (2013) 0.83
Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrob Agents Chemother (2011) 0.83
Analysis of carotenoid isomerase activity in a prototypical carotenoid cleavage enzyme, apocarotenoid oxygenase (ACO). J Biol Chem (2014) 0.82
A yeast recombination-based cloning system to produce chimeric HIV-1 viruses and express HIV-1 genes. Methods Mol Biol (2005) 0.81
High-resolution crystal structures of the photoreceptor glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with three and four-bound NAD molecules. Protein Sci (2014) 0.81
Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility. Antimicrob Agents Chemother (2012) 0.80
Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations. Curr Opin HIV AIDS (2007) 0.79
DNA suspension arrays: silencing discrete artifacts for high-sensitivity applications. PLoS One (2010) 0.77
Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc. Antimicrob Agents Chemother (2013) 0.77
Retracted Characterizing monoclonal antibody structure by carbodiimide/GEE footprinting. MAbs (2014) 0.76
The impact of viral and host elements on HIV fitness and disease progression. Curr HIV/AIDS Rep (2007) 0.76
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther (2005) 0.75
Dr. Mark A. Wainberg (1945-2017): Provocateur, Activist, and Champion for AIDS Care and Research. AIDS Res Hum Retroviruses (2017) 0.75